Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Solid TumorsNon-small Cell Lung CancerRenal Cell CarcinomaHepatocellular Carcinoma
Interventions
DRUG

Lenvatinib + Envafolimab

"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."

DRUG

Sunitinib

Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.

Trial Locations (23)

100700

RECRUITING

The Seventh Medical Center of the PLA General Hospital, Beijing

100730

NOT_YET_RECRUITING

Beijing Hospital, Beijing

110001

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

110011

RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

116011

RECRUITING

The First Affiliated Hospital of Dalian Medical University, Dalian

130012

NOT_YET_RECRUITING

THE First Hospital of Jilin University, Changchun

130028

NOT_YET_RECRUITING

Jilin Cancer Hospital, Changchun

150081

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Haerbin

233004

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

250031

RECRUITING

The 960th Hospital of the PLA Joint Logistics Support Force, Jinan

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

310020

RECRUITING

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou

330006

NOT_YET_RECRUITING

The Second Affiliater Hospital of Nanchang University, Nanchang

350001

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

361015

NOT_YET_RECRUITING

Zhongshan Hospital,Fudan University(Xiamen Branch), Xiamen

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510280

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

519000

RECRUITING

The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai

523059

RECRUITING

Dongguan People's Hospital, Dongguan

650118

RECRUITING

Yunnan Cancer Hospital, Kunming

830011

RECRUITING

The Cancer Affiliated Hospital of Xinjiang Medical College, Ürümqi

030001

RECRUITING

First Hospital of Shanxi Medical University, Taiyuan

Unknown

RECRUITING

Fudan University, Shanghai

All Listed Sponsors
lead

3D Medicines (Sichuan) Co., Ltd.

INDUSTRY

NCT05024214 - Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter